netFormulary
 Report : Medicines with links to NICE 12/07/2020 08:08:04

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Ribavirin 05.03.05 Formulary NICE TA 300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Ribavirin 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abemaciclib 08.01.05 Formulary NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Formulary NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab injection 13.05.03 Formulary NICE TA146 Adalimumab for the treatment of adults with psoriasis
Adalimumab injection 13.05.03 Formulary NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab injection 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab injection 11.04.02 Formulary NICE TA 460 Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline (epinephrine) injection 03.04.03 Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA 346 Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA 486 Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA 177 Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anastrozole 08.03.04.01 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Anastrozole 08.03.04.01 Formulary NICE CG 81 Advanced breast cancer: diagnosis and treatment
Anastrozole 08.03.04.01 Formulary NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA341 - DVT and PE treatment and secondary prevention
Apixaban 02.08.02 Formulary NICE TA245 - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA275 - Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apremilast 13.05.03 Formulary NICE TA 433 Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Formulary NICE TA419 Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Arsenic Trioxide 08.01.05 Formulary NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 08.01.05 Restricted Use NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Restricted Use NICE TA525 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA 520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Avelumab 08.01.05 Formulary NICE TA 517 Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel 08.01.05 Formulary NICE TA 559 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Baricitinib tablets 10.01.03 Formulary TA 466 Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Formulary NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bendamustine 08.01.01 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Binimetinib 08.01.05 Formulary NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02.03 Formulary NICE TA 450 Blinatumomab for previously treated Philadelphia-chromosome-negative ALL
Blinatumomab 08.02.03 Formulary NICE TA 589 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 05.03.03.02 Non Formulary NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA 260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Formulary NICE TA 478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03 Formulary NICE TA 511 Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA 516 Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA 463 Cabozantinib for previously treated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cangrelor 02.09 Formulary NICE TA351: Reducing Artherothrombotic Events
Cannabidiol 04.08.01 Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol 04.08.01 Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabis extract 10.02.02 Formulary NICE NG144 Cannabis-based medicinal products
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capsaicin 0.025% cream 10.03.02 Formulary NICE CG 177: Osteoarthritis: care and management
Capsaicin 0.075% cream 10.03.02 Formulary NICE CG 173: Neuropathic pain in adults: pharmacological management in non-specialist settings
Carfilzomib 08.01.05 Formulary NICE TA 457 Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cemiplimab 08.01.05 Formulary NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA445 Certolizumab pegol and secukinumab for psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis
Cetuximab 08.01.05 Formulary NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA 473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Ciclosporin eye drops 11.99.99.99 Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Cobimetinib 08.02.04 Non Formulary NICE TA 414 Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colistimethate sodium inhaler 05.01.07 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase clostridium histolyticum 10.03.01 Non Formulary NICE TA 459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA 422 Crizotinib for previously treated ALK-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157 - Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Non Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Non Formulary NICE TA 441 Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib monohydrate 08.01.05 Formulary NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA 418 Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Daratumumab 08.01.05 Formulary NICE TA 510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Darbepoetin Alfa 09.01.03 Formulary NICE NG8: Chronic kidney disease: managing anaemia
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA349: Diabetic Macular Oedema
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA 460 Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA 229 Dexamethasone intravitreal implant for macular oedema secondary to retinal vein occlusion
Diclofenac Gel 1% 10.03.02 Formulary NICE CG 177: Osteoarthritis: care and management
Dimethyl fumarate 08.02.04 Non Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 13.05.03 Formulary NICE TA 475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole MR capsules 02.09 Formulary NICE TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Docetaxel 08.01.05 Formulary NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Durvalumab 08.01.05 Formulary NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 09.01.03 Formulary NICE HST 1 Eculizumab for treating atypical haemolytic uraemic syndrome
Edoxaban 02.08.02 Formulary NICE TA355 - Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir/grazoprevir 05.03.03.02 Formulary NICE TA413 Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic ITP
Eluxadoline 01.05 Formulary NICE TA 471 Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Encorafenib 08.01.05 Formulary NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone tablets 02.02.03 Formulary NICE NG106: Chronic heart failure in adults: diagnosis and management
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE NG8: Chronic kidney disease: managing anaemia
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE NG8: Chronic kidney disease: managing anaemia
Eribulin 08.01.05 Formulary NICE TA 423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.05 Non Formulary NICE TA 515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Erlotinib 08.01.05 Formulary NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Erlotinib 08.01.05 Formulary NICE TA 258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA 374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 06.01.02.03 Formulary NICE TA 583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA35: Adult psoriasis
Etanercept (biosimilar) injection 13.05.03 Formulary NICE TA 103 Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept (biosimilar) injection 13.05.03 Formulary NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept biosimilar 10.01.03 Formulary NICE TA35: Adult psoriasis
Etanercept biosimilar 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept biosimilar 10.01.03 Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept biosimilar 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept biosimilar 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept injection 13.05.03 Formulary NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept injection 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etelcalcetide 09.05.01.02 Formulary NICE TA 448 Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours
Everolimus 08.01.05 Formulary NICE TA 432 Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA 421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Exemestane 08.03.04.01 Formulary NICE CG 81 Advanced breast cancer: diagnosis and treatment
Exenatide prolonged release 06.01.02.03 Formulary NICE NG 28: Type 2 diabetes in adults: management
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Non Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA 590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA 301 diabetic macular oedema
Fulvestrant 08.03.04.01 Formulary NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Fulvestrant 08.03.04.01 Formulary NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary Pancreatic cancer in adults: diagnosis and management
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemtuzumab ozogamicin 08.01.05 Formulary NICE TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir/Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03 Formulary NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis
Holoclar® 11.99.99.99 Formulary NICE TA 467 Holoclar for treating limbal stem cell deficiency after eye burns
Ibandronic Acid 06.06.02 Restricted Use NICE TA464 - Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Formulary NICE TA 429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia
Ibrutinib 08.01.05 Formulary NICE TA 491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibuprofen gel 10.03.02 Formulary NICE CG 177: Osteoarthritis: care and management
Idelalisib 08.01.05 Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Imatinib 08.01.05 Formulary NICE TA 209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA 86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA 70 Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA 326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab (biosimilar) 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab (biosimilar) 01.05.03 Formulary NICE TA 187 Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab (biosimilar) 01.05.03 Formulary NICE TA 329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis
Infliximab (biosimilar) 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab (biosimilar) 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab (biosimilar) 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab (biosimilar) for infusion 13.05.03 Formulary NICE TA 134 Infliximab for the treatment of adults with psoriasis
Infliximab (biosimilar) for infusion 13.05.03 Formulary NICE TA 134 Infliximab for the treatment of adults with psoriasis
Infliximab for infusion 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Interferon Alfa 08.02.04 Formulary NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon beta-1a 10.02 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1b 10.02.01 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Irinotecan (pegylated liposomal) 08.01 Non Formulary NICE TA 440 Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Irinotecan Hydrochloride 08.01.05 Formulary NICE CG 131 Colorectal cancer: diagnosis and management
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ivabradine 02.06.03 Formulary NICE TA 267 Ivabradine for treating chronic heart failure
Ixazomib 08.02.04 Formulary TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab injection 13.05.03 Formulary NICE TA 442 Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab injection 13.05.03 Formulary NICE TA 537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lamivudine 05.03.01 Formulary NICE CG165: Chronic Hepatitis B
Lanadelumab 03.04.03 Formulary TA 606 Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Restricted Use NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib 08.01.05 Formulary NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma
Lenalidomide 08.02.04 Formulary NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA 171 Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Formulary NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenvatinib 08.01.05 Restricted Use NICE TA 551 Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Restricted Use NICE TA 535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Restricted Use NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Letermovir 05.03.02.02 Formulary NICE TA 591 Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Letrozole 08.03.04.01 Formulary NICE CG 81 Advanced breast cancer: diagnosis and treatment
Letrozole 08.03.04.01 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and treatment
Lidocaine medicated plaster 5% 15.02 Restricted Use NICE CG173 - Neuropathic pain in adults: pharmacological management in non-specialist settings
Liposomal cytarabine-daunorubicin 08.01.05 Formulary NICE TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Lorlatinib 08.01.05 Formulary NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lusutrombopag 09.01.04 Formulary NICE TA617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Mannitol inhalation 03.07 Non Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Mepolizumab 03.04.02 Restricted Use NICE TA 431 Mepolizumab for treating severe refractory eosinophilic asthma
Methadone Hydrochloride 04.10 Formulary NICE TA 114 Methadone and Buprenorphine for management of opioid dependence
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Formulary Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Nalmefene 04.10.01 Formulary NICE TA 325 Reduction of alcohol consumption in alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA 345 Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone Hydrochloride 04.10 Formulary NICE TA 115 Naltrexone for management of opioid dependence
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Neratinib 08.01.05 Formulary NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Formulary NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 03.11 Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nintedanib 03.11 Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA 347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Niraparib 08.01.05 Formulary NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Formulary NICE TA417 Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Formulary NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Formulary NICE TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.02.04 Formulary NICE TA558 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.02.04 Formulary NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.04 Formulary NICE TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nusinersen 10.02 Formulary NICE TA 588 Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Formulary NICE TA 443 Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA 513 Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Ocrelizumab 08.02.04 Formulary NICE TA 533 Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.04 Formulary NICE TA 585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 11.08.02 Formulary NICE TA 297 Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Formulary NICE TA620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.02.04 Formulary NICE TA598 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaratumab 08.01.05 Non Formulary NICE TA 465 Olaratumab with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Osimertinib 08.02.04 Formulary NICE TA 416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Pabrinex® 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Pabrinex® 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Paclitaxel 08.01.05 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA 476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.03.04.01 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.03.04.01 Formulary NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Panitumumab 08.01.05 Formulary NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer 09.02.01.01 Formulary NICE TA623 Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib in renal cell cancer
Pegaspargase 08.01 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Peginterferon beta 1a 10.02.01 Formulary NICE TA624 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Formulary NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Formulary NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA522Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Formulary NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pentosan polysulfate sodium capsules 07.04.03 Formulary NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Formulary NICE TA 424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 1% cream 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Piracetam 04.08.01 Formulary NICE CG137: Epilepsies: diagnosis and management
Pirfenidone 03.11 Formulary NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Formulary NICE TA 427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA 451 Ponatinib for treating CML and ALL
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA 160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA 161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranibizumab 11.08.02 Formulary NICE TA 274 Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Regorafenib 08.01.05 Formulary NICE TA 488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Formulary NICE TA 555 Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Non Formulary NICE TA 514 Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Formulary NICE TA 479 Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribociclib 08.03.04.01 Restricted Use NICE TA 593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Rifaximin 05.01.07 Formulary NICE TA 337 Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risankizumab 13.05.03 Formulary NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Rituximab 08.02.03 Formulary NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 08.02.03 Formulary NICE TA 226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA 193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA 174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rituximab 10.01.03 Formulary NICE TA 308 - ANCA vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA170 - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA256 - Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA287 - Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Roflumilast 03.03.03 Formulary TA 461 Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Rucaparib 08.01.05 Formulary NICE TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab injection 10.01.03 Formulary NICE TA 445 Certolizumab pegol and secukinumab for psoriatic arthritis after inadequate response to DMARDs
Secukinumab injection 10.01.03 Formulary NICE TA 407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab injection 13.05.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab injection 13.05.03 Formulary NICE TA350: Plaque Psoriasis
Simeprevir 05.03.03.02 Non Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir/velpatasvir 05.03.03.02 Formulary NICE TA 430 Sofosbuvir–velpatasvir for treating chronic hepatitis C
sofosbuvir/velpatasvir/voxilaprevir 05.03.03.02 Formulary TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Formulary NICE TA188: Somatropin for growth failure in children
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 08.01.05 Formulary NICE TA 474 Sorafenib for treating advanced hepatocellular carcinoma
Sotagliflozin 06.01.02.03 Formulary NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
Stiripentol 04.08.01 Formulary NICE CG137: Epilepsies: diagnosis and management
Sunitinib 08.01.05 Formulary NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvac 08.02.04 Formulary NICE TA 410 Talimogene laherparepvec for treating unresectable metastatic melanoma
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tamoxifen 08.03.04.01 Formulary NICE CG 81 Advanced breast cancer: diagnosis and treatment
Tamoxifen 08.03.04.01 Formulary NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Tamoxifen 08.03.04.01 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and treatment
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Non Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA 420 Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel 08.01.05 Formulary NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tisagenlecleucel 08.01.05 Formulary NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib 08.01.05 Formulary NICE TA 512 Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA 518 Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Formulary NICE TA480: tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib 10.01.03 Formulary NICE TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary TA 183 Topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan 08.01.05 Formulary NICE TA 389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA 458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer
Trifluridine-tiparicil tablets 08.01.03 Formulary NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer
UrgoStart® 19.20 Formulary NICE MTG 40: UrgoStart for treating diabetic foot ulcers and leg ulcers
Ustekinumab 10.01.03 Formulary NICE TA 340 Ustekinumab for treating active psoriatic arthritis
Ustekinumab 01.05.03 Formulary NICE TA 456 Ustekinumab for moderately to severely active Crohn’s disease
Ustekinumab injection 13.05.03 Formulary NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab injection 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab injection 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA 487 Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Formulary NICE NG82: Age-related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vortioxetine 04.03.03 Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Zanamivir inhalation 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanamivir inhalation 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Portsmouth and South East Hampshire